[go: up one dir, main page]

US3814809A - Sustained release contraceptive composition and method of use - Google Patents

Sustained release contraceptive composition and method of use Download PDF

Info

Publication number
US3814809A
US3814809A US00197959A US19795971A US3814809A US 3814809 A US3814809 A US 3814809A US 00197959 A US00197959 A US 00197959A US 19795971 A US19795971 A US 19795971A US 3814809 A US3814809 A US 3814809A
Authority
US
United States
Prior art keywords
prostaglandin
tampon
conception
ethylene diamine
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00197959A
Inventor
M Gordon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Priority to US00197959A priority Critical patent/US3814809A/en
Application granted granted Critical
Publication of US3814809A publication Critical patent/US3814809A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Definitions

  • Contraceptive compositions are disclosed, as well as methods for preventing conception or implantation, using as dosage forms (a) a vaginal suppository and/or (b) impregnated hydrophilic polyurethane or cellulose tampons ice
  • the compositions will contain, per dosage form, from about g. to about 10 mg. of prostaglandin F or E from about 1 pg. to about 1000 pg. of oxytocine, from about 10 mg. to about 1000 mg. of copper or zinc salt of ethylene diamine tetraacetic acid.
  • COMPLETE DISCLOSURE It has long been an object of the pharmaceutical industry to discover a safe and effective method of either preventing conception or terminating a conception in the very early stages of the pregnancy.
  • composition of the present invention which comprises prostagladin (F or E oxytocin and zinc or copper salts of ethyllene diamine tetraacetic acid.
  • compositions of this invention in suitable dosage forms, comprise prostaglandin F or E oxytocin and zinc or copper salts of ethylene diamine tetraacetic acid.
  • These compositions are prepared in the form of a vaginal suppository and/or tampon by incorporating amounts of the active ingredients sufficient to prevent conception or implantation, without limiting side effects, first into a sustained release medium and then into a nontoxic conventional carrier according to accepted proceedures.
  • the compositions will contain, per dosage form, from about 100 g. to about 10 mg. of prostaglandin F or E from about 1 g. to about 1000 g. of oxytocin, from about 10 mg. to about 1000 mg. of copper or zinc salt of ethylene diamine tetraacetic acid.
  • the zinc disodium ethylene diamine tetraacetic acid and half of the prostaglandin are dissolved or suspended in water to make-up 10% of the total weight.
  • Theglycerin is then added mixing carefully to exclude incorporation of air bubbles.
  • the mixture is heated on a water bath and the gelatin added and stirred until the gelatin is dissolved.
  • the mixture is then allowed to cool and the powdered cetyl palmitate is stirred in and the total mixture is poured into chilled non-lubricated molds and allowed to stand until congealed.
  • a similar procedure is used for the carbowax suppositories, or theobroma oil may be substituted.
  • the suppositories are prepared following the conventional techniques of the pharma* ceutical chemist.
  • the active ingredients (a), (b), (c) and (d) used in the glycerin suppository example below are dissolved or suspended in 5 ml. of water and absorbed into a cylinder of hydrophilic polyurethane foam measuring aproximately 1.5" in di ameter and approximately 3" long. The water is then evaporated in vacuo or freeze dried, and the impregnated cylinder is used as a vaginal tampon.
  • Cellulose tampons are well-known in the art.
  • Conventional polyurethane foams are the reaction product of liquid polyols (polyether or polyester) and a dif-unctional isocyanate, usually toluene diisocyanate.
  • a catalyst such as tin, an amine, a flowing agent, generally water, and foaming stabilizers are also employed. The required cyclinders for tampon use are cut from the prepared foam.
  • the method in accordance with this invention comprises inserting in the animal organism one vaginal suppository and/ or impregnated tampon between one hour and twentyfour hours after exposure to conception to prevent conception or implanation.
  • the above application is repeated every 24 hours for one to seven days following the initial exposure.
  • the suppository is inserted first and then held in position by the tampon. If the vaginal suppository is used alone, a nonimpregnated tampon should be inserted immediately afterward to hold the contents in place.”
  • the preferred prostaglandins are PGF and PGE as luteolytic agents.
  • the preferred ethylene diamine tetraacetic acid salts are the zinc disodium salt and the copper disodium salt, as antizygotic agents.
  • the prostaglandins have a half life in blood serum of only ten minutes, it is necessary that a portion of the prostaglandin in the suppository or tampon be in a slow release form. This is accomplished by dissolving or suspending the prostaglandin in a melt of low melting, biodegradable wax. The wax with the prostaglandin incorporated is then either powdered, or the melt is poured over a cold surface and the Waxy material scraped off in the form of powder or flakes.
  • Among the vehicles for slow release of prostaglandin in biological fluids are cetyl palmitate, carnauba wax, lauric acid, a mixture of sodium laurate and lauric acid, a mixture of stearic acid and sodium sterate, a mixture of arachidonic acid and sodium arachidonate, and cetyl palmitate.
  • Arachidonic acid has the further advantage of being a precursor of prosta glandin F and prostaglandin E in seminal tissue, and hence it can contribute to the prostaglandin levels made available from the suppository or tampon.
  • the active ingredients (a), (b), (c) and (d) are dissolved or suspended in water to make up 10% of the total weight.
  • the glycerin is added, mixing carefully to exclude incorporation of air bubbles.
  • the mixture is heated on a water bath, the gelatin is added and then stirred until the gelatin is dissolved. This mixture is poured into chilled non-lubricated molds and allowed to stand until congealed to give a vaginal suppository.
  • the 400 pg. of PGF- may be replaced with the same amount of PGE and the zinc salt of ethylene diamine tetraacetic acid may be replaced by the copper salt.
  • EXAMPLE 2 Ingredients G./ suppository Carbowax polyethylene glycol 6000 2.5 Carbowax polyethylene glycol 1540 1.5 Water plus The carbowax suppositories are prepared following the procedure described in Example 1. The 400 pg. of PGF may be replaced with the same amount of PGE and the zinc salt of ethylene diamine tetra'acetic acid may be replaced by the copper salt.
  • EXAMPLE 3 Ingredients Water plus (a) 200 pg. PGF -5 g./tampon (b) 10 g.'oxytocin I (c) mg. of copper salt of ethylene diamine tetraacetic acid adjusted to neutral pH (d) 200 pg. PGE and 10 g. of oxytocin dissolved in 0.5 gm. of melted cetyl palmitate or similar waxy material which is then powdered after cooling
  • the active ingredients (a), (b), (c) and (d) are dissolved or suspended in water and absorbed into a cylinder of cellulose or hydrophilic polyurethane foam measuring about 1.5 inches in diameter and about three inches in length. The water is then evaporated in vacuo or freeze dried and the impregnated'cylinder is used as a vaginal tampon.
  • the 400 pg. of PGE may be replaced with the same amount of PGF and the copper salt of ethylene diamine tetracetic acid may be replaced by the zinc salt.
  • a sustained release contraceptive composition fo use in the form of a vaginal suppository or impregnated tampon comprising:
  • a contraceptive composition according to claim 1 in the form of a vaginal suppository in the form of a vaginal suppository.
  • the method of preventing conception or implantation which comprises inserting into the vagina of a mammal a sustained release composition in the form of a vaginal suppository or impregnated tampon each containing:
  • (c) from about 10 mg. to about 1000 mg. of zinc or copper salt of ethylene diamine tetraacetic acid; with a portion of (a) being dissolved or suspended in a low melting biodegradable wax.

Landscapes

  • Health & Medical Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSITIONS COMPRISING PROSTAGLANDIN F2A OR E2, OXYTOCIN, AND COPPER OR ZINC SALTS OF ETHYLENE DIAMINE TETRAACETIC ACID WITH A PORTION OF THE PROSTAGLANDIN BEING DISSOLVED IN A BIODEGRADABLE WAX; IN THE FORM OF VAGINAL SUPPOSITORIES AND OR IMPREGNATED TAMPONS AND METHODS OF PREVENTING CONCEPTION OR IMPLANTATION BY VAGINAL INSERTION OF SAID COMPOSITIONS AFTER EXPOSURE TO CONCEPTION ARE USEFUL CONTRACEPTIVE AIDS IN MAMMALS.

Description

United States Patent 3,814,809 SUSTAINED RELEASE CONTRACEPTIVE COM- POSITION AND METHOD OF USE Maxwell Gordon, De Witt, N.Y., assiguor to Bristol- Myers Company, New York, N .Y. No Drawing. Filed Nov. 11,1971, Ser. No. 197,959 Int. Cl. A61j 3/00, 3/08; A61k 27/00 U.S. Cl. 42419 15 Claims ABSTRACT THE DISCLOSURE BACKGROUND OF THE INVENTION 1. [Field of the invention The compositions of the instant invention are useful as contraceptive aids in mammals.
2. Description of the prior art A. S. M. M. Karim et a1. [British Medical Journal, 4, 621-623 (1968)] report the use of prostaglandin F in fusion in the induction of labor.
B. B. B. Pharriss [Science News, 95, 65-66 (1969)] reports the use of prostaglandin F in the prevention of conception. p C. V. R. Pickles [International Journal of Fertility, 12, 335-338 (1967)] reports prostaglandin F as the most potent of the prostaglandins in stimulating the human myometrium.
D. The Lancet, May 2, 1970 (pp. 927-928), reports the use of prostaglandins in the induction of labor or abortion. 1 E. The Lancet, January 31, 1970 (pp. 223-226) con tains a treatise on prostaglandins, including their use and chemistry.
The use of systemic prostaglandins as abortifacients has been reported in man [Karim and others, Lancet 1, 1115 (1970)], and their local use has been suggested. However, compositions with combined luteolytic and antizygotic properties have not been suggested. This invention is considered novel in the sustained release form of the prostaglandin, together with the use of copper or zinc salts of ethylene diamine tetraacetic acid as gametocidal agents, and in the use of oxytocin to improve tubal transport.
Furthermore, R. Ravenholt, Director of the U18. Ofiice of Population of the Agency for International Development has indicated (Drug Research Reports, July 21, 1971) that manufacturers should be interested in developing a special prostaglandin releasing tampon.
Contraceptive compositions are disclosed, as well as methods for preventing conception or implantation, using as dosage forms (a) a vaginal suppository and/or (b) impregnated hydrophilic polyurethane or cellulose tampons ice Preferably the compositions will contain, per dosage form, from about g. to about 10 mg. of prostaglandin F or E from about 1 pg. to about 1000 pg. of oxytocine, from about 10 mg. to about 1000 mg. of copper or zinc salt of ethylene diamine tetraacetic acid.
COMPLETE DISCLOSURE It has long been an object of the pharmaceutical industry to discover a safe and effective method of either preventing conception or terminating a conception in the very early stages of the pregnancy.
The object has been achieved by the formulation of the composition of the present invention which comprises prostagladin (F or E oxytocin and zinc or copper salts of ethyllene diamine tetraacetic acid.
The novel contraceptive compositions of this invention, in suitable dosage forms, comprise prostaglandin F or E oxytocin and zinc or copper salts of ethylene diamine tetraacetic acid. These compositions are prepared in the form of a vaginal suppository and/or tampon by incorporating amounts of the active ingredients sufficient to prevent conception or implantation, without limiting side effects, first into a sustained release medium and then into a nontoxic conventional carrier according to accepted proceedures. Preferably the compositions will contain, per dosage form, from about 100 g. to about 10 mg. of prostaglandin F or E from about 1 g. to about 1000 g. of oxytocin, from about 10 mg. to about 1000 mg. of copper or zinc salt of ethylene diamine tetraacetic acid.
In preparing the suppository dosage form the zinc disodium ethylene diamine tetraacetic acid and half of the prostaglandin (the other half being dissolved in the biodegradable low melting wax or related substance to pro vide a slow release of the prostaglandin) are dissolved or suspended in water to make-up 10% of the total weight. Theglycerin is then added mixing carefully to exclude incorporation of air bubbles. The mixture is heated on a water bath and the gelatin added and stirred until the gelatin is dissolved. The mixture is then allowed to cool and the powdered cetyl palmitate is stirred in and the total mixture is poured into chilled non-lubricated molds and allowed to stand until congealed. A similar procedure is used for the carbowax suppositories, or theobroma oil may be substituted. Thus the suppositories are prepared following the conventional techniques of the pharma* ceutical chemist.
To prepare the tampon dosage form, the active ingredients (a), (b), (c) and (d) used in the glycerin suppository example below are dissolved or suspended in 5 ml. of water and absorbed into a cylinder of hydrophilic polyurethane foam measuring aproximately 1.5" in di ameter and approximately 3" long. The water is then evaporated in vacuo or freeze dried, and the impregnated cylinder is used as a vaginal tampon.
Cellulose tampons are well-known in the art. Conventional polyurethane foams are the reaction product of liquid polyols (polyether or polyester) and a dif-unctional isocyanate, usually toluene diisocyanate. A catalyst such as tin, an amine, a flowing agent, generally water, and foaming stabilizers are also employed. The required cyclinders for tampon use are cut from the prepared foam.
The method in accordance with this invention comprises inserting in the animal organism one vaginal suppository and/ or impregnated tampon between one hour and twentyfour hours after exposure to conception to prevent conception or implanation. The above application is repeated every 24 hours for one to seven days following the initial exposure. In cases where both the suppository and the tampon are used, the suppository is inserted first and then held in position by the tampon. If the vaginal suppository is used alone, a nonimpregnated tampon should be inserted immediately afterward to hold the contents in place."
Carrying out the methods as described above reliably prevents conception or implantation with a minimum of side effects.
The preferred prostaglandins are PGF and PGE as luteolytic agents. The preferred ethylene diamine tetraacetic acid salts are the zinc disodium salt and the copper disodium salt, as antizygotic agents.
Inasmuch as the prostaglandins have a half life in blood serum of only ten minutes, it is necessary that a portion of the prostaglandin in the suppository or tampon be in a slow release form. This is accomplished by dissolving or suspending the prostaglandin in a melt of low melting, biodegradable wax. The wax with the prostaglandin incorporated is then either powdered, or the melt is poured over a cold surface and the Waxy material scraped off in the form of powder or flakes. Among the vehicles for slow release of prostaglandin in biological fluids are cetyl palmitate, carnauba wax, lauric acid, a mixture of sodium laurate and lauric acid, a mixture of stearic acid and sodium sterate, a mixture of arachidonic acid and sodium arachidonate, and cetyl palmitate. Arachidonic acid has the further advantage of being a precursor of prosta glandin F and prostaglandin E in seminal tissue, and hence it can contribute to the prostaglandin levels made available from the suppository or tampon.
The following examples illustrate the preparation of compositions of this invention and as such are not to be considered as limiting the invention set forth in the claims (a) 200 pg. PGF
(b) g. oxytocin (c) 100 mg. of zinc salt of ethylene diamine tetraacetic acid adjusted to neutral pH 55 q.s. ad
(d) 200 g. PGF and 10 pg. oxytocin dissolved in 0.5 gm. of melted cetyl palmitate which is then powdered after cooling 0.5
The active ingredients (a), (b), (c) and (d) are dissolved or suspended in water to make up 10% of the total weight. The glycerin is added, mixing carefully to exclude incorporation of air bubbles. The mixture is heated on a water bath, the gelatin is added and then stirred until the gelatin is dissolved. This mixture is poured into chilled non-lubricated molds and allowed to stand until congealed to give a vaginal suppository.
The 400 pg. of PGF- may be replaced with the same amount of PGE and the zinc salt of ethylene diamine tetraacetic acid may be replaced by the copper salt.
EXAMPLE 2 Ingredients G./ suppository Carbowax polyethylene glycol 6000 2.5 Carbowax polyethylene glycol 1540 1.5 Water plus The carbowax suppositories are prepared following the procedure described in Example 1. The 400 pg. of PGF may be replaced with the same amount of PGE and the zinc salt of ethylene diamine tetra'acetic acid may be replaced by the copper salt.
EXAMPLE 3 Ingredients Water plus (a) 200 pg. PGF -5 g./tampon (b) 10 g.'oxytocin I (c) mg. of copper salt of ethylene diamine tetraacetic acid adjusted to neutral pH (d) 200 pg. PGE and 10 g. of oxytocin dissolved in 0.5 gm. of melted cetyl palmitate or similar waxy material which is then powdered after cooling The active ingredients (a), (b), (c) and (d) are dissolved or suspended in water and absorbed into a cylinder of cellulose or hydrophilic polyurethane foam measuring about 1.5 inches in diameter and about three inches in length. The water is then evaporated in vacuo or freeze dried and the impregnated'cylinder is used as a vaginal tampon.
The 400 pg. of PGE may be replaced with the same amount of PGF and the copper salt of ethylene diamine tetracetic acid may be replaced by the zinc salt..
I claim:
1. A sustained release contraceptive composition fo use in the form of a vaginal suppository or impregnated tampon comprising:
(a) from about 100 g. to about 10 mg. of prostaglandin F or E (b) from about 1 g. to about 100 g. of oxytocin and (c) from about 10 mg. to about 1000 mg. zinc or copper salt of ethylene diamine tetraacetic acid; with a portion of (a) being dissolved or suspended in a low melting biodegradable wax.
2. A contraceptive composition according to claim 1 in the form of a vaginal suppository.
3. A contraceptive composition according to claim 1 in the form of an impregnated tampon.
4. A contraceptive composition according to claim 3 in which the impregnated tampon is cellulose.
5. A contraceptive composition according to claim 3 in which the impregnated tampon is a polyurethane foam.
6. A contraceptive composition according to claim 1 in which the amount of (a) is 400 pg., (b) is 10 pg., (0) is 100 mg.
7. A contraceptive composition according to claim 6 in which the prostaglandin is F 8. The method of preventing conception or implantation which comprises inserting into the vagina of a mammal a sustained release composition in the form of a vaginal suppository or impregnated tampon each containing:
(a) from about 100 g. to about 10 mg. of prostaglandin Fg or E (b) from about 1 g. to about 1000 pg. of oxytocin,
and
(c) from about 10 mg. to about 1000 mg. of zinc or copper salt of ethylene diamine tetraacetic acid; with a portion of (a) being dissolved or suspended in a low melting biodegradable wax.
9. The method according to claim 8 in which the insertion is 1 to 24 hours after exposure to conception. V.
10. The method according to claim 9 in which the insertion of the composition is repeated about every 24 hours for from 1 to 7 days following initial exposure to conception.
11. The method according to claim 10 in which both the suppository and tampon are inserted into the vagina.
6 12. The method according to claim 10 in which the References Cited suppository is inserted into the vagina. UNITED STATES PATENTS 13. The method according to claim 10 in Whic the 39 5 1 2 1972 Gordon 424-14 tampon is inserted into the vagina. 3,563,235 2/ 1971 Zipper 128130 14. The method according to claim 8 in which the 5 amount (a) is 400 #g., (b) is 10 g, (c) is 110 mg. SAM ROSEN Pnmary Exammer 15. The method according to claim 14 in which the -S- C X-R- prostaglandin is F 42414, 177, 289, 294, 305, 317
US00197959A 1971-11-11 1971-11-11 Sustained release contraceptive composition and method of use Expired - Lifetime US3814809A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US00197959A US3814809A (en) 1971-11-11 1971-11-11 Sustained release contraceptive composition and method of use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00197959A US3814809A (en) 1971-11-11 1971-11-11 Sustained release contraceptive composition and method of use

Publications (1)

Publication Number Publication Date
US3814809A true US3814809A (en) 1974-06-04

Family

ID=22731440

Family Applications (1)

Application Number Title Priority Date Filing Date
US00197959A Expired - Lifetime US3814809A (en) 1971-11-11 1971-11-11 Sustained release contraceptive composition and method of use

Country Status (1)

Country Link
US (1) US3814809A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062964A (en) * 1975-12-03 1977-12-13 Ciba-Geigy Corporation Antifertility-combinations
US4156604A (en) * 1978-09-15 1979-05-29 Minnesota Mining And Manufacturing Company Controlled delivery of corrosion inhibitors for silver recovery cartridges
WO1980000008A1 (en) * 1978-06-09 1980-01-10 Donald Enterprises Inc Contraceptive-antivenereal disease tampon
US4309997A (en) * 1978-06-09 1982-01-12 Donald Jack W Contraceptive and/or antivenereal disease tampon
US5672359A (en) * 1993-07-21 1997-09-30 The University Of Kentucky Research Foundation Multicompartment hard capsule with control release properties
EP3003045A4 (en) * 2013-03-15 2017-01-25 CDA Research Group, Inc. Topical copper ion treatments in the genital-rectal areas of the body
US10398733B2 (en) 2013-03-15 2019-09-03 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body
US10813948B2 (en) 2013-03-15 2020-10-27 Cda Research Group, Inc. Methods of treatment using topical copper ion formulations
US11000545B2 (en) 2013-03-15 2021-05-11 Cda Research Group, Inc. Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
US11007143B2 (en) 2013-03-15 2021-05-18 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the oral-respiratory-otic areas of the body
US11193184B2 (en) 2019-02-22 2021-12-07 Cda Research Group, Inc. System for use in producing a metal ion suspension and process of using same
US11318089B2 (en) 2013-03-15 2022-05-03 Cda Research Group, Inc. Topical copper ion treatments and methods of making topical copper ion treatments for use in various anatomical areas of the body
US12318406B2 (en) 2013-03-15 2025-06-03 Cda Research Group, Inc. Methods of treatment using topical copper ion formulations

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062964A (en) * 1975-12-03 1977-12-13 Ciba-Geigy Corporation Antifertility-combinations
WO1980000008A1 (en) * 1978-06-09 1980-01-10 Donald Enterprises Inc Contraceptive-antivenereal disease tampon
US4186742A (en) * 1978-06-09 1980-02-05 Donald Enterprises, Inc. Contraceptive-antivenereal disease tampon
US4309997A (en) * 1978-06-09 1982-01-12 Donald Jack W Contraceptive and/or antivenereal disease tampon
US4156604A (en) * 1978-09-15 1979-05-29 Minnesota Mining And Manufacturing Company Controlled delivery of corrosion inhibitors for silver recovery cartridges
US5672359A (en) * 1993-07-21 1997-09-30 The University Of Kentucky Research Foundation Multicompartment hard capsule with control release properties
US11000545B2 (en) 2013-03-15 2021-05-11 Cda Research Group, Inc. Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
US11298316B2 (en) 2013-03-15 2022-04-12 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the oral-respiratory-otic areas of the body
US10398733B2 (en) 2013-03-15 2019-09-03 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body
US10813948B2 (en) 2013-03-15 2020-10-27 Cda Research Group, Inc. Methods of treatment using topical copper ion formulations
EP3003045A4 (en) * 2013-03-15 2017-01-25 CDA Research Group, Inc. Topical copper ion treatments in the genital-rectal areas of the body
US11007143B2 (en) 2013-03-15 2021-05-18 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the oral-respiratory-otic areas of the body
US11083750B2 (en) 2013-03-15 2021-08-10 Cda Research Group, Inc. Methods of treatment using topical copper ion formulations
US12329779B2 (en) 2013-03-15 2025-06-17 Cda Research Group, Inc. Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
US11253544B2 (en) 2013-03-15 2022-02-22 Cda Research Group, Inc. Methods of treatment using topical copper ion formulations
AU2014235693B2 (en) * 2013-03-15 2017-10-05 Cda Research Group, Inc. Topical copper ion treatments in the genital-rectal areas of the body
US11318089B2 (en) 2013-03-15 2022-05-03 Cda Research Group, Inc. Topical copper ion treatments and methods of making topical copper ion treatments for use in various anatomical areas of the body
US12318406B2 (en) 2013-03-15 2025-06-03 Cda Research Group, Inc. Methods of treatment using topical copper ion formulations
US11717535B2 (en) 2013-03-15 2023-08-08 Cda Research Group, Inc. Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
US11857514B2 (en) 2013-03-15 2024-01-02 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body
US12171867B2 (en) 2013-03-15 2024-12-24 Cda Research Group, Inc. Topical copper ion treatments and methods of making topical copper ion treatments for use in various anatomical areas of the body
US11459638B2 (en) 2019-02-22 2022-10-04 Cda Research Group, Inc. System for use in producing a metal ion suspension and process of using same
US11193184B2 (en) 2019-02-22 2021-12-07 Cda Research Group, Inc. System for use in producing a metal ion suspension and process of using same

Similar Documents

Publication Publication Date Title
US3814809A (en) Sustained release contraceptive composition and method of use
US3639561A (en) Vaginal suppositories and impregnated tampons
EP0088394B1 (en) Stable, effervescent vaginal suppository composition and suppositories made therefrom
US3234091A (en) Shaped medicaments and process for their manufacture
US5069906A (en) Intra-vaginal device and method
US4804674A (en) Vaginal pharmaceutical composition
US3918452A (en) Tampons impregnated with contraceptive compositions
US4469671A (en) Contraceptive device
Williams et al. Adipose tissue metabolism in pregnancy: the lipolytic effect of human placental lactogen
US2149005A (en) Shaped medicinal preparation
US3876757A (en) Contraception agent
SK77797A3 (en) Unitary vaginal dosage form useful as a local contraceptive and/or for combatting sexually transmitted diseases and/or hiv
PH26079A (en) Long lasting contraceptive suppository composition and method of use
FI85105C (en) suppository
PT77621B (en) Process for the preparation of liofilized pharmaceutical compo-sitions containing aminocaproic acid
US4322399A (en) Vaginal suppository
US2550622A (en) Ointment base and iodine ointment
US4164573A (en) Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal
CA1216237A (en) Contraceptive composition
US3639562A (en) Vaginal suppositories and impregnated tampons
US4031202A (en) Controlled release contraceptive article
US2055063A (en) Suppository medication
US4323548A (en) Vaginal suppository for contraception, having a predetermined lactalbumin content
Gamble An improved test of spermicidal activity without dilution or mixing
US4493699A (en) Contraceptive methods